Calliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 Data
March 13, 2023 at 11:15 AM EDT
Calliditas Therapeutics AB(NASDAQ: CALT) announcedtopline resultsfrom the Phase 3 clinical trial NefIgArd, which ...